Page last updated: 2024-10-15

alpha-hydroxyglutarate and Glioma

alpha-hydroxyglutarate has been researched along with Glioma in 120 studies

2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.
2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.

Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Research Excerpts

ExcerptRelevanceReference
" Lithium chloride was recently proved efficient in inhibiting glioma cell migration."7.80Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β. ( Chan, KG; Fu, Y; Hu, F; Liang, A; Zheng, Y, 2014)
"Lithium chloride was recently proved efficient in inhibiting glioma cell migration."5.40Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β. ( Chan, KG; Fu, Y; Hu, F; Liang, A; Zheng, Y, 2014)
"Previous ex vivo spectroscopic data from tissue samples revealed differences in phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH wildtype (IDHwt) gliomas."3.91In vivo Metabolic Profiles as Determined by ( Bähr, O; Franz, K; Hattingen, E; Pilatus, U; Steinbach, J; Wenger, KJ, 2019)
" However, in isocitrate dehydrogenase (IDH)-mutant gliomas, (13)C labeling is obscured in oncometabolite 2-hydroxyglutaric acid (2 HG) by glutamate and glutamine, prompting development of a simple method to resolve the metabolites."3.81Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas. ( Bachoo, RM; Baek, HM; DeBerardinis, RJ; Kovacs, Z; Maher, EA; Malloy, CR; Mashimo, T; Mickey, B; Pichumani, K; Ratnakar, J, 2015)
" Lithium chloride was recently proved efficient in inhibiting glioma cell migration."3.80Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β. ( Chan, KG; Fu, Y; Hu, F; Liang, A; Zheng, Y, 2014)
"Mixed oligoastrocytoma is losing popularity as a diagnostic term because most cases will fall into either the FA or OD category."2.52Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. ( Macaulay, RJ, 2015)
"Across glioma as well as several hematologic malignancies, mutations in IDH1 and IDH2 have shown prognostic value."2.46Cancer-associated IDH mutations: biomarker and therapeutic opportunities. ( Bittinger, MA; Fantin, VR; Su, SM; Yen, KE, 2010)
"Cancer cachexia is characterized by weight loss and skeletal muscle wasting."1.91Oncometabolite D-2-hydroxyglutarate-dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia. ( Cheng, D; Chi, M; Ding, J; Guo, C; Hao, J; Huang, J; Sun, X; Wang, Y; Xin, B; Xincai, Z; Xu, R; Yang, Q; Yuan, T; Zhang, H; Zhang, J; Zheng, S; Zhou, S; Zhu, X, 2023)
"Uncontrolled seizures in patients with gliomas have a significant impact on quality of life and morbidity, yet the mechanisms through which these tumors cause seizures remain unknown."1.72IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation. ( Bachani, M; Dowdy, T; Fayed, I; Gilbert, M; Inati, SK; Jahanipour, J; Khan, A; Ksendzovsky, A; Larion, M; Maric, D; Mortazavi, A; Owotade, J; Steiner, J; Walbridge, S; Wu, J; Yang, CZ; Zaghloul, KA, 2022)
"Lower grade mIDH1 gliomas are classified into 2 molecular subgroups: 1p/19q codeletion/TERT-promoter mutations or inactivating mutations in α-thalassemia/mental retardation syndrome X-linked (ATRX) and TP53."1.62Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. ( Alghamri, MS; Appelman, H; Carney, SV; Castro, MG; Edwards, MB; Garcia-Fabiani, MB; Gauss, JC; Haase, S; Kadiyala, P; Kleer, CG; Li, D; Liu, Y; Lowenstein, PR; Moon, JJ; Núñez, FJ; Nunez, FM; Schwendeman, A; Sun, Y; Taher, A; Yu, M; Zhao, L, 2021)
"The sensitivity and specificity was 89."1.48Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. ( Choi, C; Lassen-Ramshad, Y; Lukacova, S; Maher, EA; Mickey, B; Parm Ulhøi, B; Sangill, R; Tietze, A; von Oettingen, G; Østergaard, L, 2018)
"Eighteen patients with brain tumors of probable glial origin participated in this study."1.43MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T. ( Bisdas, S; Braun, C; Chadzynski, GL; Engelmann, J; Ernemann, U; Ethofer, T; Hagberg, GE; Pohmann, R; Scheffler, K; Schittenhelm, J; Shajan, G; Skardelly, M; Tabatabai, G; Ziemann, U, 2016)
"Lithium chloride was recently proved efficient in inhibiting glioma cell migration."1.40Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β. ( Chan, KG; Fu, Y; Hu, F; Liang, A; Zheng, Y, 2014)
"Patients with intrinsic glial brain tumors (n = 27) underwent structural and spectroscopic magnetic resonance imaging prior to surgery."1.38Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. ( Albert Thomas, M; Bittinger, MA; Chou, AP; Cloughesy, TF; Driggers, E; Fantin, VR; Jang, HG; Kornblum, HI; Lai, A; Liau, LM; Nagarajan, R; Pope, WB; Prins, RM; Salamon, N; Schenkein, DP; Soto, H; Su, SM; Wilson, N; Wu, H; Yen, KE; Yong, WH, 2012)
"Gliomas were found to have elevated levels of similar histone repressive marks."1.38IDH mutation impairs histone demethylation and results in a block to cell differentiation. ( Abdel-Wahab, O; Berger, SL; Chan, TA; Edwards, CR; Figueroa, ME; Kapoor, GS; Khanin, R; Levine, RL; Lu, C; Mellinghoff, IK; Melnick, A; O'Rourke, DM; Rohle, D; Thompson, CB; Turcan, S; Ward, PS; Wellen, KE, 2012)

Research

Studies (120)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (0.83)29.6817
2010's90 (75.00)24.3611
2020's29 (24.17)2.80

Authors

AuthorsStudies
Chou, FJ1
Liu, Y6
Lang, F1
Yang, C2
Juskanič, D1
Mištinová, JP1
Hollý, S1
Sekerešová, M1
Koleják, K1
Pátrovič, L1
Mortazavi, A1
Fayed, I1
Bachani, M1
Dowdy, T1
Jahanipour, J1
Khan, A1
Owotade, J1
Walbridge, S1
Inati, SK1
Steiner, J1
Wu, J2
Gilbert, M1
Yang, CZ1
Larion, M1
Maric, D1
Ksendzovsky, A1
Zaghloul, KA1
Winkler, F1
Tuna, G1
Dal-Bekar, NE1
Akay, A1
Rükşen, M1
İşlekel, S1
İşlekel, GH1
Chuntova, P1
Yamamichi, A1
Chen, T1
Narayanaswamy, R1
Ronseaux, S1
Hudson, C1
Tron, AE1
Hyer, ML1
Montoya, M1
Mende, AL1
Nejo, T1
Downey, KM1
Diebold, D1
Lu, M2
Nicolay, B2
Okada, H1
Autry, AW1
Lafontaine, M1
Jalbert, L1
Phillips, E1
Phillips, JJ5
Villanueva-Meyer, J1
Berger, MS2
Chang, SM3
Li, Y2
Fujita, Y1
Nunez-Rubiano, L1
Dono, A1
Bellman, A1
Shah, M1
Rodriguez, JC1
Putluri, V1
Kamal, AHM1
Putluri, N1
Riascos, RF1
Zhu, JJ1
Esquenazi, Y1
Ballester, LY1
Di Stefano, AL1
Nichelli, L1
Berzero, G1
Valabregue, R1
Touat, M1
Capelle, L1
Pontoizeau, C1
Bielle, F1
Lerond, J1
Giry, M1
Villa, C1
Baussart, B1
Dehais, C1
Galanaud, D1
Baldini, C1
Savatovsky, J1
Dhermain, F1
Deelchand, DK1
Ottolenghi, C1
Lehéricy, S1
Marjańska, M2
Branzoli, F1
Sanson, M1
Shi, DD2
Anand, S1
Abdullah, KG1
McBrayer, SK3
Afsari, F1
McIntyre, TM2
Iwahashi, H1
Nagashima, H2
Tanaka, K2
Uno, T1
Hashiguchi, M1
Maeyama, M1
Somiya, Y1
Komatsu, M1
Hirose, T1
Itoh, T2
Sasaki, R2
Sasayama, T2
Gunn, K1
Myllykoski, M1
Cao, JZ1
Ahmed, M1
Huang, B2
Rouaisnel, B1
Diplas, BH2
Levitt, MM1
Looper, R2
Doench, JG1
Ligon, KL4
Kornblum, HI2
Yan, H7
Duy, C1
Godley, LA1
Koivunen, P2
Losman, JA2
Cao, C1
Zhang, L1
Sorensen, MD1
Reifenberger, G1
Kristensen, BW1
Lin, F3
Zhu, X1
Hao, J1
Zhang, H1
Chi, M1
Wang, Y1
Huang, J1
Xu, R1
Xincai, Z1
Xin, B1
Sun, X1
Zhang, J4
Zhou, S1
Cheng, D1
Yuan, T1
Ding, J1
Zheng, S1
Guo, C1
Yang, Q1
Zhang, Y5
Pusch, S5
Innes, J1
Sidlauskas, K1
Ellis, M1
Lau, J1
El-Hassan, T1
Aley, N1
Launchbury, F1
Richard-Loendt, A1
deBoer, J1
Chen, S1
Wang, L4
von Deimling, A6
Li, N1
Brandner, S1
Bhavya, B1
Anand, CR1
Madhusoodanan, UK1
Rajalakshmi, P1
Krishnakumar, K1
Easwer, HV1
Deepti, AN1
Gopala, S1
Huang, LE1
Cuccarini, V1
Antelmi, L1
Pollo, B2
Paterra, R1
Calatozzolo, C1
Nigri, A1
DiMeco, F1
Eoli, M1
Finocchiaro, G3
Brenna, G1
Tramacere, I1
Bruzzone, MG3
Anghileri, E2
Karpel-Massler, G2
Nguyen, TTT1
Shang, E1
Siegelin, MD2
Li, X2
Strasser, B1
Jafari-Khouzani, K2
Thapa, B1
Small, J1
Cahill, DP8
Dietrich, J3
Batchelor, TT6
Andronesi, OC6
Huang, RY2
Lin, A1
Tiwari, V5
Mashimo, T4
An, Z4
Vemireddy, V2
Piccirillo, S1
Askari, P2
Hulsey, KM2
Zhang, S3
de Graaf, RA2
Patel, TR5
Pan, E5
Mickey, BE6
Maher, EA8
Bachoo, RM4
Choi, C9
Xiong, N1
Gao, X1
Zhao, H1
Cai, F1
Zhang, FC1
Yuan, Y1
Liu, W2
He, F1
Zacharias, LG1
Lin, H1
Vu, HS1
Xing, C1
Yao, DX1
Chen, F1
Luo, B1
Sun, W1
DeBerardinis, RJ3
Xu, H2
Ge, WP1
Molloy, AR2
Najac, C2
Viswanath, P5
Lakhani, A1
Subramani, E2
Batsios, G2
Radoul, M2
Gillespie, AM2
Pieper, RO5
Ronen, SM6
Bystricky, P1
Kasubova, I1
Richterova, R1
Lasabova, Z1
Kolarovszki, B1
Thamim, M1
Thirumoorthy, K1
Waitkus, MS2
Kadiyala, P1
Carney, SV1
Gauss, JC1
Garcia-Fabiani, MB1
Haase, S1
Alghamri, MS1
Núñez, FJ1
Yu, M1
Taher, A1
Nunez, FM1
Li, D1
Edwards, MB1
Kleer, CG1
Appelman, H1
Sun, Y1
Zhao, L1
Moon, JJ1
Schwendeman, A1
Lowenstein, PR1
Castro, MG1
Bhandari, A1
Sharma, C1
Ibrahim, M1
Riggs, M1
Jones, R1
Lasocki, A1
Dimitrov, IE1
Ganji, SK4
Levy, M3
Malloy, CR4
Lan, C1
Li, H1
Wang, X1
Zhang, R1
Yuan, X1
Wu, T1
Ma, X1
Lucca, LE1
Hafler, DA1
Jiang, B2
Xia, J1
Zhao, W2
Wu, Y1
Shi, M2
Luo, L1
Zhou, H2
Chen, A2
Ma, H2
Zhao, Q1
Suleman, M2
Zhou, L2
Wang, J2
He, Y3
Hung, LM1
Mak, TW2
Li, Q2
Han, CH1
Baxter, J2
Pinho, MC1
Mazor, T1
Chesnelong, C1
Pankov, A1
Jalbert, LE2
Hong, C1
Hayes, J1
Smirnov, IV1
Marshall, R1
Souza, CF1
Shen, Y1
Noushmehr, H1
Jones, SJM1
Marra, MA1
Cairncross, JG2
Perry, A1
Nelson, SJ3
Bollen, AW1
Molinaro, AM1
Bengtsson, H1
Olshen, AB1
Weiss, S2
Luchman, HA2
Costello, JF1
Wenger, KJ1
Hattingen, E1
Franz, K1
Steinbach, J1
Bähr, O1
Pilatus, U1
Ishida, CT1
Bianchetti, E1
Shu, C1
Tsujiuchi, T1
Banu, MA1
Garcia, F1
Roth, KA1
Bruce, JN1
Canoll, P2
Kopinja, J1
Sevilla, RS1
Levitan, D1
Dai, D1
Vanko, A1
Spooner, E1
Ware, C1
Forget, R1
Hu, K1
Kral, A1
Spacciapoli, P1
Kennan, R1
Jayaraman, L1
Pucci, V1
Perera, S1
Zhang, W1
Fischer, C1
Lam, MH1
Berrington, A1
Voets, NL1
Larkin, SJ2
de Pennington, N2
Mccullagh, J2
Stacey, R2
Schofield, CJ2
Jezzard, P2
Clare, S2
Cadoux-Hudson, T2
Plaha, P2
Ansorge, O2
Emir, UE2
Izquierdo-Garcia, JL1
Ong, WQ1
Zhou, M1
Zhou, Y1
Liao, H1
Rowland, BC1
Kong, X1
Arvold, ND1
Reardon, DA1
Wen, PY2
Lin, AP1
Longuespée, R1
Wefers, AK1
De Vita, E1
Miller, AK2
Reuss, DE1
Wick, W2
Herold-Mende, C2
Kriegsmann, M1
Schirmacher, P1
Linninger, A1
Hartung, GA1
Liu, BP1
Mirkov, S1
Tangen, K1
Lukas, RV1
Unruh, D1
James, CD1
Sarkaria, JN1
Horbinski, C2
Arrillaga-Romany, IC1
Ly, KI1
Bogner, W3
Ratai, EM1
Reitz, K1
Iafrate, AJ3
Gerstner, ER2
Chi, AS4
Rosen, BR4
Kanamori, M1
Maekawa, M1
Shibahara, I1
Saito, R1
Chonan, M1
Shimada, M1
Sonoda, Y2
Kumabe, T1
Watanabe, M1
Mano, N1
Tominaga, T2
Liu, M1
Wen, S1
Ouyang, C1
Wang, H1
Huang, X1
Bunse, L1
Bunse, T1
Sahm, F2
Sanghvi, K1
Friedrich, M1
Alansary, D1
Sonner, JK1
Green, E1
Deumelandt, K1
Kilian, M1
Neftel, C1
Uhlig, S1
Kessler, T1
von Landenberg, A1
Berghoff, AS1
Marsh, K1
Steadman, M1
Zhu, D2
Wiestler, B1
Breckwoldt, MO1
Al-Ali, R1
Karcher-Bausch, S1
Bozza, M1
Oezen, I1
Kramer, M1
Meyer, J1
Habel, A1
Eisel, J1
Poschet, G1
Weller, M2
Preusser, M1
Nadji-Ohl, M1
Thon, N1
Burger, MC1
Harter, PN1
Ratliff, M1
Harbottle, R1
Benner, A1
Schrimpf, D1
Okun, J1
Turcan, S3
Kaulfuss, S1
Hess-Stumpp, H1
Bieback, K1
Plate, KH1
Hänggi, D1
Dorsch, M1
Suvà, ML2
Niemeyer, BA1
Platten, M1
Suh, CH1
Kim, HS1
Jung, SC1
Choi, CG1
Kim, SJ1
Park, GHJ1
Yang, SH1
Baek, HM2
Mayers, JR1
DiNatale, GJ1
Khanal, J1
Chakraborty, AA1
Sarosiek, KA1
Briggs, KJ1
Robbins, AK1
Sewastianik, T1
Shareef, SJ1
Olenchock, BA1
Parker, SJ1
Tateishi, K1
Spinelli, JB1
Islam, M1
Haigis, MC1
Looper, RE1
Bernstein, BE2
Carrasco, RD1
Asara, JM1
Metallo, CM1
Yennawar, NH1
Vander Heiden, MG4
Kaelin, WG3
Hatanpaa, KJ3
Xia, YK1
Li, CJ1
Zhang, JY2
Yi, W1
Qin, ZY1
Chen, L1
Shi, ZF1
Quan, K1
Yang, ZX1
Guan, KL2
Xiong, Y2
Ng, HK1
Ye, D1
Hua, W1
Mao, Y1
Berger, RS1
Ellmann, L1
Reinders, J1
Kreutz, M1
Stempfl, T1
Oefner, PJ1
Dettmer, K1
Santos, RD1
Juratli, TA1
Peitzsch, M1
Geiger, K1
Schackert, G1
Eisenhofer, G1
Krex, D1
Rohle, D2
Popovici-Muller, J1
Palaskas, N1
Grommes, C1
Campos, C2
Tsoi, J1
Clark, O1
Oldrini, B1
Komisopoulou, E1
Kunii, K1
Pedraza, A1
Schalm, S1
Silverman, L1
Miller, A1
Wang, F1
Yang, H2
Chen, Y1
Kernytsky, A1
Rosenblum, MK1
Biller, SA1
Su, SM5
Brennan, CW1
Chan, TA2
Graeber, TG1
Yen, KE5
Mellinghoff, IK3
Ganji, S1
Hulsey, K1
Madan, A2
Kovacs, Z3
Dimitrov, I1
Pichumani, K2
Mendelsohn, D1
Mickey, B3
Malloy, C1
Bachoo, R1
Deberardinis, R1
Maher, E2
Guilhamon, P1
Eskandarpour, M1
Halai, D1
Wilson, GA1
Feber, A1
Teschendorff, AE1
Gomez, V1
Hergovich, A1
Tirabosco, R1
Fernanda Amary, M1
Baumhoer, D1
Jundt, G1
Ross, MT1
Flanagan, AM1
Beck, S1
Rapalino, O2
Gerstner, E3
Chi, A1
Sorensen, AG2
Chaumeil, MM1
Larson, PE1
Yoshihara, HA1
Danforth, OM1
Vigneron, DB1
Gilbert, MR1
Neltner, J1
Pu, H1
Morris, A1
Sunkara, M1
Pittman, T1
Kyprianou, N1
Schweizer, L1
Beck, AC1
Lehmler, JM1
Weissert, S1
Balss, J2
Fu, Y1
Zheng, Y1
Chan, KG1
Liang, A1
Hu, F1
Ohka, F1
Ito, M1
Ranjit, M1
Senga, T1
Motomura, A1
Motomura, K1
Saito, K1
Kato, K1
Kato, Y2
Wakabayashi, T1
Soga, T1
Natsume, A1
Bertolino, N1
Marchionni, C1
Ghielmetti, F1
Burns, B1
Minati, L1
Santagata, S1
Eberlin, LS1
Norton, I1
Calligaris, D1
Feldman, DR1
Ide, JL1
Liu, X1
Wiley, JS1
Vestal, ML1
Ramkissoon, SH1
Orringer, DA1
Gill, KK1
Dunn, IF1
Dias-Santagata, D1
Jolesz, FA1
Golby, AJ1
Cooks, RG1
Agar, NY1
Pope, WB3
Wen, H1
Cho, HR2
Yun, T1
Kim, H2
Park, CK2
Lee, SH2
Choi, SH2
Park, S2
Liu, Z1
Yao, Y1
Kogiso, M1
Zheng, B1
Deng, L1
Qiu, JJ1
Dong, S1
Lv, H1
Gallo, JM1
Li, XN1
Song, Y2
Natsumeda, M1
Igarashi, H1
Nomura, T1
Ogura, R1
Tsukamoto, Y1
Kobayashi, T1
Aoki, H1
Okamoto, K1
Kakita, A1
Takahashi, H1
Nakada, T1
Fujii, Y1
Oizel, K1
Gratas, C1
Nadaradjane, A1
Oliver, L1
Vallette, FM1
Pecqueur, C1
Pellegatta, S1
Valletta, L1
Corbetta, C1
Patanè, M1
Zucca, I1
Riccardi Sirtori, F1
Fogliatto, G1
Isacchi, A1
Lombardi, G2
Corona, G1
Bellu, L1
Della Puppa, A2
Pambuku, A1
Fiduccia, P1
Bertorelle, R1
Gardiman, MP1
D'Avella, D1
Toffoli, G1
Zagonel, V2
Ratnakar, J1
Macaulay, RJ1
Loebel, F2
Voets, N1
Al-Qahtani, K1
de la Fuente, MI1
Young, RJ1
Rubel, J1
Rosenblum, M1
Tisnado, J1
Briggs, S1
Arevalo-Perez, J1
Cross, JR1
Straley, K1
Dong, C1
Thomas, A1
Omuro, AA1
Nolan, CP1
Pentsova, E1
Kaley, TJ1
Oh, JH1
Noeske, R1
Gutin, PH1
Holodny, AI1
Yen, K1
DeAngelis, LM1
Thakur, SB1
Flavahan, WA1
Drier, Y1
Liau, BB1
Gillespie, SM1
Venteicher, AS1
Stemmer-Rachamimov, AO1
Heo, H1
Kim, S1
Lee, HH1
Xu, WJ1
Fathi, AT1
Nahed, BV1
Wander, SA1
Borger, DR1
Hu, R1
Thabet, A1
Perry, AM1
Joseph, CP1
Muzikansky, A1
Bisdas, S1
Chadzynski, GL1
Braun, C1
Schittenhelm, J1
Skardelly, M1
Hagberg, GE1
Ethofer, T1
Pohmann, R1
Shajan, G1
Engelmann, J1
Tabatabai, G1
Ziemann, U1
Ernemann, U1
Scheffler, K1
Irino, Y1
Sato, N1
Takeuchi, Y1
Kyotani, K1
Mukasa, A1
Mizukawa, K1
Sakata, J1
Yamamoto, Y1
Hosoda, K1
Kohmura, E1
Kalinina, J2
Ahn, J2
Devi, NS1
Olson, JJ1
Glantz, M1
Smith, T1
Kim, EL1
Giese, A1
Jensen, RL1
Chen, CC1
Carter, BS1
Mao, H2
He, M2
Van Meir, EG2
Gonzalez, GR1
Unkelbach, J1
Shih, HA1
Kingsbury, JM1
Shamaprasad, N1
Billmyre, RB1
Heitman, J1
Cardenas, ME1
Johannessen, TA1
Mukherjee, J1
Ohba, S1
Bjerkvig, R1
Carbonneau, M1
M Gagné, L1
Lalonde, ME1
Germain, MA1
Motorina, A1
Guiot, MC1
Secco, B1
Vincent, EE1
Tumber, A1
Hulea, L1
Bergeman, J1
Oppermann, U1
Jones, RG1
Laplante, M1
Topisirovic, I1
Petrecca, K1
Huot, MÉ1
Mallette, FA1
Sulkowski, PL1
Corso, CD1
Robinson, ND1
Scanlon, SE1
Purshouse, KR1
Bai, H1
Sundaram, RK1
Hegan, DC1
Fons, NR1
Breuer, GA1
Mishra-Gorur, K1
De Feyter, HM1
Surovtseva, YV1
Kachman, M1
Halene, S1
Günel, M1
Glazer, PM1
Bindra, RS1
Raisanen, JM2
McNeil, SS1
Sheppard, CA1
Oliver, D1
Battiste, J1
Barnett, S1
Madden, CJ2
Tietze, A1
Parm Ulhøi, B1
Sangill, R1
Lassen-Ramshad, Y1
Lukacova, S1
Østergaard, L1
von Oettingen, G1
Dang, L1
White, DW1
Gross, S2
Bennett, BD2
Bittinger, MA3
Driggers, EM1
Fantin, VR4
Jang, HG2
Jin, S1
Keenan, MC1
Marks, KM1
Prins, RM2
Ward, PS2
Liau, LM3
Rabinowitz, JD2
Cantley, LC1
Thompson, CB2
Komotar, RJ1
Starke, RM1
Sisti, MB1
Connolly, ES1
Smeitink, J1
Bhagwat, N1
Levine, RL2
Seltzer, MJ1
Joshi, AD1
Gao, P1
Thomas, AG1
Ferraris, DV1
Tsukamoto, T1
Rojas, CJ1
Slusher, BS1
Dang, CV1
Riggins, GJ1
Xu, W1
Yang, Y1
Wang, P2
Kim, SH1
Ito, S1
Xiao, MT1
Liu, LX1
Jiang, WQ1
Liu, J1
Wang, B1
Frye, S1
Xu, YH1
Lei, QY1
Zhao, SM1
Reitman, ZJ3
Jin, G3
Karoly, ED1
Spasojevic, I3
Yang, J2
Kinzler, KW1
Bigner, DD3
Vogelstein, B1
Batinic-Haberle, I1
Schmidt-Kittler, O1
Capper, D2
Koch, A1
Langhans, CD2
Okun, JG2
Scott, JG1
Basanta, D1
Chinnaiyan, P1
Swanson, KR1
Anderson, AR1
Simon, M1
Tonn, JC1
Hartmann, C1
Albert Thomas, M1
Nagarajan, R1
Salamon, N1
Chou, AP1
Yong, WH1
Soto, H2
Wilson, N1
Driggers, E1
Schenkein, DP1
Lai, A2
Cloughesy, TF2
Wu, H1
Yu, L1
Qi, ST1
Li, ZY1
Kim, GS1
Batchelor, T1
Tzika, AA1
Elkhaled, A1
Yoshihara, HAI1
Parvataneni, R1
Srinivasan, R1
Bourne, G1
Cha, S1
Rakheja, D1
Yang, XL1
Marin-Valencia, I1
Pascual, JM1
Lee, S1
Duncan, CG2
Lopez, G1
Lu, G1
Ramkissoon, S1
Joensuu, P1
Bergmann, U1
Travins, J1
Verhaak, RG1
Lu, C1
Kapoor, GS1
Abdel-Wahab, O1
Edwards, CR1
Khanin, R1
Figueroa, ME1
Melnick, A1
Wellen, KE1
O'Rourke, DM1
Berger, SL1
Carroll, A1
Yu, Q1
Mancheno, DE1
Wu, S1
Liu, F1
Sasaki, M1
Knobbe, CB1
Itsumi, M1
Elia, AJ1
Harris, IS1
Chio, II1
Cairns, RA1
McCracken, S1
Wakeham, A1
Haight, J1
Ten, AY1
Snow, B1
Ueda, T1
Inoue, S1
Yamamoto, K1
Ko, M1
Rao, A1
Lazovic, J1
Piccioni, D1
Lou, JR1
Li, S1
Mirsadraei, L1
Yong, W1
Prins, R1
Ellingson, BM1
Gooden, DM1
Rasheed, BA1
Yang, R1
Lopez, GY1
McLendon, RE1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171]180 participants (Anticipated)Observational2022-10-25Recruiting
Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency[NCT02021526]Phase 1/Phase 20 participants (Actual)Interventional2015-12-31Withdrawn (stopped due to NIH funding resulted in new clinical trial)
Metabolic Characterization of Space Occupying Lesions of the Brain Using in Vivo MR- (Spectroscopic) Imaging at 3 Tesla and 7 Tesla[NCT04233788]55 participants (Anticipated)Observational2021-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

15 reviews available for alpha-hydroxyglutarate and Glioma

ArticleYear
D-2-Hydroxyglutarate in Glioma Biology.
    Cells, 2021, 09-07, Volume: 10, Issue:9

    Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Brain Neoplasms; Carcinogenesis; Cell Transformation,

2021
DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.
    Journal of neuro-oncology, 2023, Volume: 162, Issue:3

    Topics: Brain Neoplasms; DNA Damage; Glioma; Humans; Isocitrate Dehydrogenase; Mutation

2023
To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
    Cellular and molecular neurobiology, 2020, Volume: 40, Issue:1

    Topics: Animals; Carcinogenesis; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation; Treatment O

2020
Friend or foe-IDH1 mutations in glioma 10 years on.
    Carcinogenesis, 2019, 11-25, Volume: 40, Issue:11

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenas

2019
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2

    Topics: Brain Neoplasms; Clinical Trials as Topic; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic;

2021
The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.
    Neuroradiology, 2021, Volume: 63, Issue:11

    Topics: Brain Neoplasms; Diagnostic Tests, Routine; Glioblastoma; Glioma; Glutarates; Humans; Isocitrate Deh

2021
2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.
    Neuro-oncology, 2018, 11-12, Volume: 20, Issue:12

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Spectrosco

2018
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
    Nature communications, 2013, Volume: 4

    Topics: Bile Duct Neoplasms; Bone Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Chondrosa

2013
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:9

    Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Mag

2013
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Brain tumor pathology, 2015, Volume: 32, Issue:1

    Topics: Antibodies, Monoclonal; Arginine; Biomarkers, Tumor; Brain Neoplasms; Catalysis; Cytosol; Glioma; Gl

2015
Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Cancer control : journal of the Moffitt Cancer Center, 2015, Volume: 22, Issue:2

    Topics: Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; DNA Helicases; Genes, p53; Glioma; Glutarates; Huma

2015
Isocitrate dehydrogenase mutations in gliomas.
    Neuro-oncology, 2016, Volume: 18, Issue:1

    Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Ketogl

2016
2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas.
    Expert review of neurotherapeutics, 2010, Volume: 10, Issue:4

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation

2010
Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
    Oncogene, 2010, Dec-09, Volume: 29, Issue:49

    Topics: Biomarkers, Tumor; Central Nervous System Neoplasms; Glioma; Glutarates; Hematologic Neoplasms; Huma

2010
Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas.
    Chinese medical journal, 2010, Volume: 123, Issue:24

    Topics: Adult; Age Factors; Brain Neoplasms; Genes, p53; Glioma; Glutarates; Humans; Isocitrate Dehydrogenas

2010

Trials

3 trials available for alpha-hydroxyglutarate and Glioma

ArticleYear
Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Neuro-oncology, 2018, 08-02, Volume: 20, Issue:9

    Topics: Adult; Aged; Brain Neoplasms; Female; Follow-Up Studies; Glioma; Glutarates; Humans; Isocitrate Dehy

2018
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Nature communications, 2018, 04-16, Volume: 9, Issue:1

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Monitoring; Enzyme

2018
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jul-29, Volume: 111, Issue:30

    Topics: Brain Neoplasms; Female; Glioma; Glutarates; Humans; Intraoperative Care; Magnetic Resonance Imaging

2014

Other Studies

102 other studies available for alpha-hydroxyglutarate and Glioma

ArticleYear
Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment.
    Magma (New York, N.Y.), 2022, Volume: 35, Issue:1

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Spectrosco

2022
IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation.
    Neuro-oncology, 2022, 09-01, Volume: 24, Issue:9

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation; Quality of Life; Se

2022
Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.
    Neuro-oncology, 2022, 09-01, Volume: 24, Issue:9

    Topics: Epilepsy; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; TOR Serine-Threonine Kinases

2022
Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
    Journal of neuropathology and experimental neurology, 2022, 06-20, Volume: 81, Issue:7

    Topics: Brain Neoplasms; Circulating Tumor DNA; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Mutati

2022
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:5

    Topics: Animals; Cancer Vaccines; Glioma; Glutarates; HLA-A2 Antigen; HLA-DR1 Antigen; Humans; Immune Checkp

2022
Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
    Journal of neuro-oncology, 2022, Volume: 159, Issue:1

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Inositol; Isocitrate Dehydrogenase; Magnetic Resonance

2022
IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    Journal of neuro-oncology, 2022, Volume: 159, Issue:2

    Topics: Biomarkers; Brain Neoplasms; Circulating Tumor DNA; Glioma; Glutarates; Humans; Isocitrate Dehydroge

2022
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of
    Neurology, 2023, 01-03, Volume: 100, Issue:1

    Topics: Brain Neoplasms; Follow-Up Studies; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Magnetic R

2023
D-2-Hydroxyglutarate Inhibits Calcineurin Phosphatase Activity to Abolish NF-AT Activation and IL-2 Induction in Stimulated Lymphocytes.
    Journal of immunology (Baltimore, Md. : 1950), 2023, 02-15, Volume: 210, Issue:4

    Topics: Calcineurin; Calcium; Glioma; Humans; Interleukin-2; Jurkat Cells; Lymphocytes

2023
2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma.
    Journal of neurosurgery, 2023, 08-01, Volume: 139, Issue:2

    Topics: Adult; Brain Neoplasms; Brain Stem Neoplasms; Female; Glioma; Humans; Image-Guided Biopsy; Isocitrat

2023
(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
    Cancer discovery, 2023, 06-02, Volume: 13, Issue:6

    Topics: Cell Transformation, Neoplastic; DNA Methylation; Glioma; Glutarates; Histone Demethylases; Histones

2023
D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.
    Journal of neuropathology and experimental neurology, 2023, 10-20, Volume: 82, Issue:11

    Topics: Astrocytoma; Brain; Brain Neoplasms; Cell Proliferation; Endothelial Cells; Glioma; Humans; Isocitra

2023
Oncometabolite D-2-hydroxyglutarate-dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia.
    Communications biology, 2023, Sep-23, Volume: 6, Issue:1

    Topics: Animals; Cachexia; Glioma; Humans; Mice; Muscle Fibers, Skeletal; Muscular Atrophy

2023
Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E.
    Cancer research, 2019, Oct-01, Volume: 79, Issue:19

    Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Endoplasmic Reticulum Stress; Gene Expression R

2019
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:2

    Topics: Biomarkers; Feasibility Studies; Female; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Magne

2020
Novel IDH1-Targeted Glioma Therapies.
    CNS drugs, 2019, Volume: 33, Issue:12

    Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Gl

2019
Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
    Radiology, 2020, Volume: 294, Issue:3

    Topics: Adult; Brain; Brain Neoplasms; Female; Glioma; Glutarates; Humans; Image Interpretation, Computer-As

2020
Whole-Brain MR Spectroscopy Imaging of Brain Tumor Metabolites.
    Radiology, 2020, Volume: 294, Issue:3

    Topics: Brain; Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Spe

2020
In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.
    Magnetic resonance in medicine, 2020, Volume: 84, Issue:3

    Topics: Animals; Brain Neoplasms; Computer Simulation; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase;

2020
Using arterial-venous analysis to characterize cancer metabolic consumption in patients.
    Nature communications, 2020, 06-23, Volume: 11, Issue:1

    Topics: Acetylcarnitine; Adult; Aged; Agmatine; Biomarkers, Tumor; Blood; Blood Chemical Analysis; Blood Glu

2020
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
    Theranostics, 2020, Volume: 10, Issue:19

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy

2020
Quantitative analysis of 2-hydroxyglutarate as a controversial oncometabolite in malignant gliomas.
    Neoplasma, 2020, Volume: 67, Issue:6

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation

2020
Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective.
    European biophysics journal : EBJ, 2020, Volume: 49, Issue:7

    Topics: Brain Neoplasms; Catalytic Domain; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutari

2020
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
    The Journal of clinical investigation, 2021, 02-15, Volume: 131, Issue:4

    Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cellular Reprogramming; Chemoradiotherapy; Ga

2021
Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm.
    Magnetic resonance in medicine, 2021, Volume: 86, Issue:4

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Lipids; Magnetic Resonance Spectroscopy

2021
Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma.
    International journal of cancer, 2021, 12-15, Volume: 149, Issue:12

    Topics: Animals; Biomarkers, Tumor; Brain; Brain Neoplasms; Disease Models, Animal; Female; Glioma; Glutarat

2021
Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment.
    The Journal of clinical investigation, 2017, Apr-03, Volume: 127, Issue:4

    Topics: Animals; CD8-Positive T-Lymphocytes; Chemokine CXCL10; Chemokine CXCL9; Glioma; Glutarates; Humans;

2017
IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation.
    Cell reports, 2017, 04-11, Volume: 19, Issue:2

    Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Culture Media, Serum-Free; Gene Expression Reg

2017
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Chinese clinical oncology, 2017, Volume: 6, Issue:3

    Topics: Brain Neoplasms; Cell Line, Tumor; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutara

2017
Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
    Magnetic resonance in medicine, 2018, Volume: 79, Issue:4

    Topics: Adult; Biomarkers; Brain Neoplasms; Echo-Planar Imaging; Female; Glioma; Glutarates; Humans; Image P

2018
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 10-03, Volume: 114, Issue:40

    Topics: Brain Neoplasms; DNA Copy Number Variations; DNA Methylation; Epigenomics; Gene Amplification; Gene

2017
In vivo Metabolic Profiles as Determined by
    Clinical neuroradiology, 2019, Volume: 29, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Diagnosis, Diffe

2019
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
    Nature communications, 2017, 10-20, Volume: 8, Issue:1

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Astrocytoma; bcl-X Protein; Brain Neop

2017
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
    Scientific reports, 2017, 10-23, Volume: 7, Issue:1

    Topics: Adult; Animals; Brain; Brain Neoplasms; Enzyme Inhibitors; Female; Gene Expression Profiling; Glioma

2017
A comparison of 2-hydroxyglutarate detection at 3 and 7 T with long-TE semi-LASER.
    NMR in biomedicine, 2018, Volume: 31, Issue:3

    Topics: Adult; Brain Neoplasms; Choline; Creatine; Female; Glioma; Glutarates; Humans; Isocitrate Dehydrogen

2018
2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.
    Cancer research, 2018, 05-01, Volume: 78, Issue:9

    Topics: Animals; Autophagy; Biomarkers; Biopsy; Cell Line, Tumor; Endoplasmic Reticulum; Gene Expression Reg

2018
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
    Acta neuropathologica communications, 2018, 03-02, Volume: 6, Issue:1

    Topics: Biomarkers, Tumor; Brain; Brain Chemistry; Brain Neoplasms; Cryopreservation; Glioma; Glutarates; Hu

2018
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
    Neuro-oncology, 2018, 08-02, Volume: 20, Issue:9

    Topics: Central Nervous System; Diffusion; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Models, The

2018
Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry.
    Brain tumor pathology, 2018, Volume: 35, Issue:2

    Topics: Biomarkers, Tumor; Central Nervous System Neoplasms; Chromatography, Liquid; Gene Deletion; Glioma;

2018
IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53.
    The Journal of biological chemistry, 2018, 06-22, Volume: 293, Issue:25

    Topics: Animals; Arginine; Brain Neoplasms; Carcinogenesis; Cell Proliferation; Gene Expression Regulation,

2018
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
    Nature medicine, 2018, Volume: 24, Issue:8

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Cell Prolife

2018
900MHz 1H-/13C-NMR analysis of 2-hydroxyglutarate and other brain metabolites in human brain tumor tissue extracts.
    PloS one, 2018, Volume: 13, Issue:9

    Topics: Brain; Brain Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy; Chloroform; Deuterium Oxide; Glio

2018
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.
    Cell, 2018, 09-20, Volume: 175, Issue:1

    Topics: Cell Line, Tumor; Glioma; Glutamic Acid; Glutarates; Homeostasis; Humans; Isocitrate Dehydrogenase;

2018
3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo.
    Magnetic resonance in medicine, 2019, Volume: 81, Issue:2

    Topics: Acoustics; Adult; Algorithms; Astrocytoma; Brain; Brain Mapping; Brain Neoplasms; Contrast Media; Ec

2019
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry.
    Laboratory investigation; a journal of technical methods and pathology, 2019, Volume: 99, Issue:4

    Topics: Adult; Brain Neoplasms; Gas Chromatography-Mass Spectrometry; Glioma; Glutarates; Humans; Immunohist

2019
Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations.
    Scientific reports, 2019, 05-15, Volume: 9, Issue:1

    Topics: Alcohol Oxidoreductases; Cell Line, Tumor; Chromatography, Liquid; Glioma; Glutarates; HCT116 Cells;

2019
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
    Scientific reports, 2019, 07-19, Volume: 9, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Astrocytes; Brain Neoplasms; Cell Cycle Proteins; Cel

2019
Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Neuro-oncology, 2013, Volume: 15, Issue:6

    Topics: Adult; Aged; Brain Neoplasms; Chromatography, Liquid; Disease Progression; Female; Glioma; Glutarate

2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
    Science (New York, N.Y.), 2013, May-03, Volume: 340, Issue:6132

    Topics: Animals; Benzeneacetamides; Cell Differentiation; Cell Transformation, Neoplastic; Enzyme Inhibitors

2013
A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
    NMR in biomedicine, 2013, Volume: 26, Issue:10

    Topics: Adult; Aspartic Acid; Brain Neoplasms; gamma-Aminobutyric Acid; Glioma; Glutamic Acid; Glutamine; Gl

2013
Non-invasive in vivo assessment of IDH1 mutational status in glioma.
    Nature communications, 2013, Volume: 4

    Topics: Animals; Brain Neoplasms; Carbon Isotopes; Cell Extracts; Cell Line, Tumor; DNA Mutational Analysis;

2013
Autophagy and oxidative stress in gliomas with IDH1 mutations.
    Acta neuropathologica, 2014, Volume: 127, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Cel

2014
D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
    Acta neuropathologica communications, 2014, Feb-14, Volume: 2

    Topics: Brain Neoplasms; Cell Movement; Cell Survival; Glioma; Glutarates; Green Fluorescent Proteins; HEK29

2014
Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β.
    Molecular biology reports, 2014, Volume: 41, Issue:6

    Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Glutarates; Glycogen Synt

2014
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:6

    Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C

2014
Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study.
    Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 2014, Volume: 30, Issue:6

    Topics: Aspartic Acid; Brain; Glioma; Glutamic Acid; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation;

2014
Intraoperative mass spectrometry of tumor metabolites.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jul-29, Volume: 111, Issue:30

    Topics: Brain Neoplasms; Female; Glioma; Glutarates; Humans; Intraoperative Care; Magnetic Resonance Imaging

2014
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Journal of neurochemistry, 2015, Volume: 132, Issue:2

    Topics: Benzeneacetamides; Cell Line; Chromatography, Liquid; Citric Acid Cycle; Glioma; Glutarates; Humans;

2015
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Journal of medicinal chemistry, 2014, Oct-23, Volume: 57, Issue:20

    Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S

2014
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
    Acta neuropathologica communications, 2014, Nov-07, Volume: 2

    Topics: Adult; Aged; Brain; Brain Neoplasms; Female; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; K

2014
D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.
    Cell death & disease, 2015, Mar-26, Volume: 6

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Etoposide; Gene Expression Regulation, Neoplastic;

2015
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
    Acta neuropathologica communications, 2015, Jan-21, Volume: 3

    Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Down-Regulati

2015
Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    The oncologist, 2015, Volume: 20, Issue:5

    Topics: Adult; Aged; Biomarkers, Tumor; Female; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Middle

2015
Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.
    Analytical biochemistry, 2015, Jul-15, Volume: 481

    Topics: Carbon Isotopes; Glioma; Glutamic Acid; Glutamine; Glutarates; Humans; Isocitrate Dehydrogenase; Mag

2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-01, Volume: 22, Issue:7

    Topics: Biomarkers; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Female; Glioma; Glutarates; Humans;

2016
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
    Cancer research, 2016, Jan-01, Volume: 76, Issue:1

    Topics: Adult; Brain Neoplasms; Case-Control Studies; Female; Glioma; Glutarates; Humans; Isocitrate Dehydro

2016
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
    Neuro-oncology, 2016, Volume: 18, Issue:2

    Topics: Adult; Aged; Brain Neoplasms; Female; Follow-Up Studies; Glioma; Glutarates; Humans; Isocitrate Dehy

2016
Insulator dysfunction and oncogene activation in IDH mutant gliomas.
    Nature, 2016, Jan-07, Volume: 529, Issue:7584

    Topics: Base Sequence; Binding Sites; CCCTC-Binding Factor; Cell Cycle Proteins; Cell Proliferation; Cell Tr

2016
On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Animals; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Female

2016
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
    The oncologist, 2016, Volume: 21, Issue:2

    Topics: Adult; Aged; Biomarkers, Tumor; Female; Genotype; Glioma; Glutarates; Humans; Isocitrate Dehydrogena

2016
MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.
    Journal of magnetic resonance imaging : JMRI, 2016, Volume: 44, Issue:4

    Topics: Alcohol Oxidoreductases; Algorithms; Biomarkers, Tumor; Brain Neoplasms; Glioma; Glutarates; Humans;

2016
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Neuro-oncology, 2016, Volume: 18, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Brain Neoplasms; Glioma; Glutamate Dehydroge

2016
Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Brain; Brain Neoplasms; Cerebrospinal Fluid; Female; Glioma; Glutara

2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Neuro-oncology, 2016, Volume: 18, Issue:11

    Topics: Adult; Aged, 80 and over; Brain; Brain Neoplasms; Female; Glioma; Glutarates; Humans; Isocitrate Deh

2016
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
    Human molecular genetics, 2016, 08-15, Volume: 25, Issue:16

    Topics: Aldehyde Dehydrogenase; Alleles; Cell Line, Tumor; DNA, Mitochondrial; Glioma; Glutarates; Humans; I

2016
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
    Molecular cancer research : MCR, 2016, Volume: 14, Issue:10

    Topics: Astrocytes; Benzeneacetamides; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transform

2016
Urine 2-Hydroxyglutarate in Glioma.
    The oncologist, 2016, Volume: 21, Issue:8

    Topics: Brain Neoplasms; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Mutation

2016
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway.
    Nature communications, 2016, 09-14, Volume: 7

    Topics: Astrocytes; beta-Transducin Repeat-Containing Proteins; Citric Acid Cycle; Glioma; Glutarates; HEK29

2016
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
    Science translational medicine, 2017, 02-01, Volume: 9, Issue:375

    Topics: Animals; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; Female; Glioma; Glutarates; Homo

2017
Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 11-20, Volume: 34, Issue:33

    Topics: Adolescent; Adult; Aged; Biomarkers; Brain Chemistry; Brain Neoplasms; Female; Glioma; Glutarates; H

2016
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Journal of neurosurgery, 2018, Volume: 128, Issue:2

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; DNA Mutational Analysis; Female; Glioma; Glutarates; Human

2018
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Nature, 2009, Dec-10, Volume: 462, Issue:7274

    Topics: Arginine; Brain Neoplasms; Catalytic Domain; Cell Line; Crystallography, X-Ray; Disease Progression;

2009
IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate.
    Neurosurgery, 2010, Volume: 66, Issue:4

    Topics: Gene Expression Regulation, Neoplastic; Glioma; Glutarates; Humans; Hypoxia-Inducible Factor 1, alph

2010
Metabolism, gliomas, and IDH1.
    The New England journal of medicine, 2010, Mar-25, Volume: 362, Issue:12

    Topics: Brain Neoplasms; Genetic Markers; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Isocitrates;

2010
Metabolic syndromes and malignant transformation: where the twain shall meet.
    Science translational medicine, 2010, Oct-20, Volume: 2, Issue:54

    Topics: Cell Transformation, Neoplastic; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Mye

2010
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
    Cancer research, 2010, Nov-15, Volume: 70, Issue:22

    Topics: Blotting, Western; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Dose-Response Relat

2010
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Cancer cell, 2011, Jan-18, Volume: 19, Issue:1

    Topics: 5-Methylcytosine; Amino Acid Substitution; Animals; Binding, Competitive; Biocatalysis; Caenorhabdit

2011
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Feb-22, Volume: 108, Issue:8

    Topics: Cell Line, Tumor; Dipeptides; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Metabolome; Muta

2011
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    PloS one, 2011, Feb-04, Volume: 6, Issue:2

    Topics: Binding, Competitive; Brain Neoplasms; Cells, Cultured; Down-Regulation; Enzyme Activation; Genes, D

2011
Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry.
    Brain pathology (Zurich, Switzerland), 2012, Volume: 22, Issue:1

    Topics: Brain Neoplasms; Fixatives; Formaldehyde; Gas Chromatography-Mass Spectrometry; Glioma; Glutarates;

2012
Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?
    Neuro-oncology, 2011, Volume: 13, Issue:12

    Topics: Brain Neoplasms; Evolution, Molecular; Glioma; Glutarates; Glycolysis; Humans; Isocitrate Dehydrogen

2011
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
    International journal of cancer, 2012, Aug-01, Volume: 131, Issue:3

    Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; Glutarates; Humans; Isocitrate Dehy

2012
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Journal of neuro-oncology, 2012, Volume: 107, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Chromatography, Liquid; DNA, Neo

2012
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
    Science translational medicine, 2012, Jan-11, Volume: 4, Issue:116

    Topics: Adult; Aged; Biopsy; Brain Neoplasms; Epilepsy; Female; Glioma; Glutarates; Humans; Isocitrate Dehyd

2012
Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
    Science translational medicine, 2012, Jan-11, Volume: 4, Issue:116

    Topics: Amino Acid Sequence; Base Sequence; Brain Neoplasms; DNA Mutational Analysis; Glioma; Glutarates; Hu

2012
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
    Nature medicine, 2012, Jan-26, Volume: 18, Issue:4

    Topics: Algorithms; Aspartic Acid; Brain; Brain Mapping; Brain Neoplasms; Choline; Creatine; Female; Glioma;

2012
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
    Nature medicine, 2012, Jan-26, Volume: 18, Issue:4

    Topics: Algorithms; Aspartic Acid; Brain; Brain Mapping; Brain Neoplasms; Choline; Creatine; Female; Glioma;

2012
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
    Nature medicine, 2012, Jan-26, Volume: 18, Issue:4

    Topics: Algorithms; Aspartic Acid; Brain; Brain Mapping; Brain Neoplasms; Choline; Creatine; Female; Glioma;

2012
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
    Nature medicine, 2012, Jan-26, Volume: 18, Issue:4

    Topics: Algorithms; Aspartic Acid; Brain; Brain Mapping; Brain Neoplasms; Choline; Creatine; Female; Glioma;

2012
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
    Nature, 2012, Feb-15, Volume: 483, Issue:7390

    Topics: Astrocytes; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dioxyg

2012
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Nature, 2012, Feb-15, Volume: 483, Issue:7390

    Topics: 3T3-L1 Cells; Adipocytes; Animals; Astrocytes; Cell Differentiation; Cell Line, Tumor; Cell Lineage;

2012
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
    Journal of molecular medicine (Berlin, Germany), 2012, Volume: 90, Issue:10

    Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Child; Child, Preschool; DNA Mutational Analysis; F

2012
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
    Genes & development, 2012, Sep-15, Volume: 26, Issue:18

    Topics: Animals; Basement Membrane; Brain; Collagen; Gene Knock-In Techniques; Genotype; Glioma; Glutarates;

2012
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
    Neuro-oncology, 2012, Volume: 14, Issue:12

    Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Glioma; Glutarates; Humans; Immunohistochemistry;

2012
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
    Cancer research, 2013, Jan-15, Volume: 73, Issue:2

    Topics: Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Genotype; Glioblastoma; Glioma; Glutarates; Humans;

2013